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Introduction: State of the local immune response of the gastrointestinal tract,
provided by secretory immunoglobulin A (SIgA), in children with CF remains the
least studied.
Material and Methods: The study included 31 children with CF in age from 5
to 17.5 years. The level of SIgA and serum IgA, IgM, IgG in coproﬁltrates was
measured by radial immunodiffusion (A. Mancini, A. Carbonara 1965). Antiserum
to the alpha chain, identifying serum and SIgA, and antiserum to secretory compo-
nent (SC), determines only the SIgA were used. A control group was represented
by 20 healthy people of the same age group.
Results: SIgA was detected in 21 children with CF (67.7%), while in other patients
the rate was zero. The level of SIgA in coproﬁltrates of all CF patients was signif-
icantly reduced (3.52±0.83mg%, p< 0.001) in comparison with healthy children.
Free SC practically did not differ from that of healthy children (1.39±0.46mg%,
p> 0.05). Serum IgA was determined in every third child with CF (35.5%) at
an average concentration equal to 0.82±0.35mg%, which is apparently caused by
increased vascular permeability due to inﬂammation in the intestine. Serum IgM
and IgG in coproﬁltrates of children with CF were found in isolated cases: in 6
and 4 patients respectively. Direct correlation between level of SIgA and patients’
age (r = +0.352, p< 0.05), the presence of CFTRdel21kb and delF508 mutations in
patients (r = +0.36, p< 0.05) were identiﬁed.
Conclusion: Our studies have illustrated a signiﬁcant violation of the ﬁrst line
speciﬁc defense of intestinal mucosa in CF patients provided by SIgA, and
dependence of the level of its reduction from the genotype and age of the patients.
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Colomycin (colistimethate sodium) is bactericidal against a range of gram-negative
bacteria, including Pseudomonas aeruginosa, a key pathogen in CF. It has been
demonstrated to be safe and effective; however, patients frequently report headaches
and paraesthesia during therapy. We have recently demonstrated drug speciﬁc
lymphocytes in patients with neurotoxicity suggesting an immune aetiology.
In this study we measured speciﬁc IgE and IgG against Colomycin (Phadia, Uppsala,
Sweden) in a cohort of patients at the Adult CF Unit in Leeds. In total 31 patients
were tested, 17 had previous neurotoxicity (10 headaches, 7 paraesthesia), 7 had
non-immediate urticarial skin reactions, and 7 were controls (4 tolerant, 3 naı¨ve).
The results are outlined in Table 1. All speciﬁc IgE antibodies were negative. The
colomycin speciﬁc IgG levels seen in the neurotoxicity group were signiﬁcantly
elevated compared to the control group (p = 0.006).
Speciﬁc antibodies to colomycin
Colomycin Speciﬁc
IgE (kUA/l)
Colomycin Speciﬁc
IgG (mgA/l)
Neurotoxicity (n = 17) <0.35 42.69 (2.14–174)
Non-immediate skin reactions (n = 7) <0.35 10.40 (2.29–33.6)
Tolerant/naive controls (n = 7) <0.35 3.19 (0–16.8)
This data further supports an immunological basis to neurological symptoms rather
than the long held belief that it relates just to direct drug toxicity. We hypothesise
that the headaches are the result of immune complex deposition due to binding
of the speciﬁc IgG; perhaps by causing a low grade cerebral vasculitis. This
phenomenon is seen usually in autoimmune disease but can rarely occur with
drugs such allopurinol. Further work is needed to prospectively assess symptomatic
patients during colomycin therapy.
